Analysis Of Income And Expense [Abstract]

ChemoMetec - Filing #1366642

Concept	2022-07-01 to 2023-06-30	2022-07-01 to 2023-06-30	2022-07-01 to 2023-06-30	2022-07-01 to 2023-06-30	2022-07-01 to 2023-06-30	2021-07-01 to 2022-06-30	2021-07-01 to 2022-06-30	2021-07-01 to 2022-06-30	2021-07-01 to 2022-06-30	2021-07-01 to 2022-06-30
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	—	442,274 DKK	—	—	427,160 DKK	—	—	—	—
Material income and expense [abstract]
Other finance income	—	—	2,516 DKK	—	—	1,883 DKK	—	—	—	—
Expenses by nature [abstract]
Raw materials and consumables used	—	—	60,359 DKK	—	—	55,354 DKK	—	—	—	—
Classes of employee benefits expense [abstract]
Employee benefits expense	—	—	99,644 DKK	—	—	120,060 DKK	—	—	—	—
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Depreciation and amortisation expense [abstract]
Depreciation and amortisation expense	—	—	20,469 DKK	—	—	20,038 DKK	—	—	—	—
Other expenses, by nature	—	—	44,716 DKK	—	—	41,301 DKK	—	—	—	—
Disclosure of attribution of expenses by nature to their function [text block]	—	—	—	—	—	—	—	—	—	—
Disclosure of attribution of expenses by nature to their function [abstract]
Disclosure of attribution of expenses by nature to their function [line items]
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	104,415 DKK	71,497 DKK	175,904 DKK	- DKK	8,000 DKK	159,943 DKK	- DKK	- DKK	22,000 DKK	159,921 DKK